Raia Drogasil S.A. (OTCMKTS:RADLY – Get Free Report) saw unusually-strong trading volume on Friday. 272,606 shares were traded during trading, an increase of 212% from the previous session’s volume of 87,507 shares. The stock last traded at $4.15 and had previously closed at $4.15.
Raia Drogasil Stock Performance
The company has a market cap of $5.47 billion and a P/E ratio of 83.20. The business has a 50 day moving average price of $3.71 and a two-hundred day moving average price of $3.88. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.58 and a current ratio of 1.41.
Raia Drogasil (OTCMKTS:RADLY – Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $0.05 EPS for the quarter, hitting analysts’ consensus estimates of $0.05. Raia Drogasil had a return on equity of 18.20% and a net margin of 2.97%.The business had revenue of $2.17 billion for the quarter, compared to analysts’ expectations of $2.32 billion. On average, sell-side analysts anticipate that Raia Drogasil S.A. will post 0.17 earnings per share for the current year.
Raia Drogasil Company Profile
Raia Drogasil SA, known as RD Saúde, is a Brazilian healthcare and pharmacy retail company. It operates a nationwide network of drugstores under the Raia and Drogasil brands, offering prescription medicines, over-the-counter products, vitamins, personal-care items, cosmetics and other health-related merchandise.
The company also provides digital shopping and delivery services through its online channels, supporting customers with prescription fulfillment and access to pharmacy products.
Read More
- Five stocks we like better than Raia Drogasil
- Alphabet Introduces Gemini Agent—Can It Trigger a Breakout?
- Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November Earnings
- Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
- Arista Networks Plugs Into All-Time Highs
Receive News & Ratings for Raia Drogasil Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raia Drogasil and related companies with MarketBeat.com's FREE daily email newsletter.
